CI

At a glance

ClinicalIndex Comparison Record
Phase 3Unknown· 180 target
Drug / intervention
Lidocaine 5% patch +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04169854
NCT04169854Phase 3Unknown

Pre-emptive Topical Lidocaine 5% Plaster for Prevention of Post-craniotomy Pain : a Protocol for a Randomized, Triple Blind, Placebo-controlled Trail

Beijing Tiantan Hospital·interventional·Posted Nov 20, 2019·Updated Oct 20, 2020

In Brief

A Phase 3 clinical trial evaluating Lidocaine 5% patch and Placebo patch for Postoperative Pain and Lidocaine. Targeting 180 participants across 1 site.

Detailed Summary

Postcraniotomy pain remains a common phenomenon in the neurosurgery field. Managements for postcraniotomy pain are to be standardised and optimized. In the proposed study, the investigators aim to provide a novel regional non-invasive prophylactic strategy for postcraniotomy pain by utilizing Lidocaine 5% plaster.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesChina
Collaborators--

Timeline

Phase 3UnknownOverdue
2020202120222023202420252026
First PostedNov 20, 2019
Enrollment StartOct 15, 2020
Primary CompletionJan 1, 2023
TodayJul 1, 2026
Enrollment to primary: 2.2 yearsPosted 6.6 years ago

Interventions

Lidocaine 5% patchdrug

The Lidocaine 5% Patch will be applied to cover the marked incision site and head-holders sites for 3 consecutive preoperative days between 6:00 P.M. to 6:00 A.M.. Research assistants will be responsible for instructing patients to cover the patches correctly.

Placebo patchdrug

The Placebo Patch will be applied to cover the marked incision site and head-holders sites for 3 consecutive preoperative days between 6:00 P.M. to 6:00 A.M.. Research assistants will be responsible for instructing patients to cover the patches correctly.